Literature DB >> 32930620

Incidence and risk factors of carbapenem-resistant Enterobacteriaceae infection in intensive care units: a matched case-control study.

Fahad A S Aleidan1,2, Hind Alkhelaifi3, Aljouharah Alsenaid3, Haya Alromaizan3, Fajer Alsalham3, Alhanouf Almutairi3, Khalid Alsulaiman2, Abdel Galil Abdel Gadir1.   

Abstract

BACKGROUND: Carbapenem-resistant Enterobacteriaceae (CRE) infection is associated with intensive care admissions, morbidity, and mortality. Our study aimed to determine the incidence, risk factors, and patient outcomes of CRE in the ICU units.
METHODS: This was a retrospective matched case-control study of patients admitted to ICUs. Patients who have positive cultures of CRE and carbapenem-susceptible Enterobacteriaceae (CSE) were included in the study. Patients were randomly selected from a pool of CSE subjects in a ratio of 1:1 of CRE to CSE as control patients.
RESULTS: The infection rate with CRE among all patients admitted to ICUs was 7.6% and the incidence of CRE infection was 5.6 per 1,000 person-day. The risk factors independently associated with CRE infection were: Higher Sequential Organ Failure Assessment (SOFA) and Nutrition Risk in Critically ill (NUTRIC) scores, prolonged ICU length of stay (LOS), previous surgery, dialysis and mechanical ventilation during ICU stay, and previous use of aminoglycoside and carbapenems.
CONCLUSION: In this retrospective study, the incidence of CRE infection was relatively elevated in patients admitted to ICU. Patients with high SOFA and NUTRIC scores, prolonged ICU LOS, previous surgery, dialysis and mechanical ventilation, and prior aminoglycosides and carbapenems use, may have an increased risk of CRE infection.

Entities:  

Keywords:  Infection; carbapenem-resistant Enterobacteriaceae ; incidence; intensive care; risk factors

Year:  2020        PMID: 32930620     DOI: 10.1080/14787210.2020.1822736

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  6 in total

1.  Early dexamethasone use as a protective measure in non-mechanically ventilated critically ill patients with COVID-19: a multicenter, cohort study.

Authors:  Khalid Al Sulaiman; Ghazwa B Korayem; Khalid Eljaaly; Ali F Altebainawi; Omar Al Harbi; Hisham A Badreldin; Abdullah Al Harthi; Ghada Al Yousif; Ramesh Vishwakarma; Shorouq Albelwi; Rahaf Almutairi; Maha Almousa; Razan Alghamdi; Alaa Alhubaishi; Abdulrahman Alissa; Aisha Alharbi; Rahmah Algarni; Sarah Al Homaid; Khawla Al Qahtani; Nada Akhani; Abdulaleam Al Atassi; Ghassan Al Ghamdi; Ohoud Aljuhani
Journal:  Sci Rep       Date:  2022-06-13       Impact factor: 4.996

2.  Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study.

Authors:  Ohoud Aljuhani; Khalid Al Sulaiman; Adel Alshabasy; Khalid Eljaaly; Abdulrahman I Al Shaya; Haytham Noureldeen; Mohammed Aboudeif; Bodoor Al Dosari; Amina Alkhalaf; Ghazwa B Korayem; Muneera M Aleissa; Hisham A Badreldin; Shmeylan Al Harbi; Abdullah Alhammad; Ramesh Vishwakarma
Journal:  BMC Infect Dis       Date:  2021-11-01       Impact factor: 3.090

3.  A Nomogram With Six Variables Is Useful to Predict the Risk of Acquiring Carbapenem-Resistant Microorganism Infection in ICU Patients.

Authors:  Jin Zhang; Wanjun Liu; Wei Shi; Xuanxuan Cui; Yu Liu; Zongqing Lu; Wenyan Xiao; Tianfeng Hua; Min Yang
Journal:  Front Cell Infect Microbiol       Date:  2022-03-25       Impact factor: 5.293

4.  Construction of a Prediction Model for the Mortality of Elderly Patients with Diabetic Nephropathy.

Authors:  Li Wang; Yan Lv
Journal:  J Healthc Eng       Date:  2022-09-12       Impact factor: 3.822

5.  The impact of HMG-CoA reductase inhibitors use on the clinical outcomes in critically ill patients with COVID-19: A multicenter, cohort study.

Authors:  Khalid Al Sulaiman; Ohoud Aljuhani; Ghazwa B Korayem; Ali F Altebainawi; Shmeylan Al Harbi; Abdulrahman Al Shaya; Hisham A Badreldin; Raed Kensara; Abdullah F Alharthi; Jahad Alghamdi; Ahad Alawad; Rand Alotaibi; Abdullah Kharbosh; Hessa Al Muqati; Abdulmohsen Alhuwahmel; Mohammed Almusallam; Ghada Albarrak; Ibrahim Al Sulaihim; Bader Alanazi; Bodoor S Al-Dosari; Ramesh Vishwakarma; Alawi S Alsaeedi; Ghassan Al Ghamdi; Hadeel Alkofide; Hasan M Al-Dorzi
Journal:  Front Public Health       Date:  2022-08-11

6.  Evaluation of inhaled nitric oxide (iNO) treatment for moderate-to-severe ARDS in critically ill patients with COVID-19: a multicenter cohort study.

Authors:  Khalid Al Sulaiman; Ghazwa B Korayem; Ali F Altebainawi; Shmeylan Al Harbi; Abdulrahman Alissa; Abdullah Alharthi; Raed Kensara; Amjaad Alfahed; Ramesh Vishwakarma; Hussain Al Haji; Naif Almohaimid; Omar Al Zumai; Fahad Alrubayan; Abdulmajid Asiri; Nasser Alkahtani; Abdulaziz Alolayan; Samiah Alsohimi; Nawal Melibari; Alaa Almagthali; Seba Aljahdali; Abeer A Alenazi; Alawi S Alsaeedi; Ghassan Al Ghamdi; Omar Al Faris; Joud Alqahtani; Jalal Al Qahtani; Khalid A Alshammari; Khalil I Alshammari; Ohoud Aljuhani
Journal:  Crit Care       Date:  2022-10-03       Impact factor: 19.334

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.